Amgen Archives - Vista Partners LLC | HomeVista Partners LLC

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

by John F. Heerdink, Jr. 13 hours ago 53Views 0Likes

NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets. A New Board for a…

Alpha Therapy’s Radiopharma Unicorn Surge -( $AZN $BMY $NVS $IBB $XBI )

by John F. Heerdink, Jr. March 13, 2026 206Views 0Likes

Biotech innovators are pioneering RNA‑optimized fusions for targeted alpha therapies (TATs), positioning themselves as first‑movers in the broader radiopharma market that is exploding with demand for precision cancer killers. Radiopharma Market Momentum Builds Billions The radiopharma sector, blending alpha‑particle precision with smart…

GeoVax Joins the “Post‑Prasad” Party With a Well‑Timed Signal to Buyers and Bureaucrats -( $GOVX $INO $TNXP $VRTX $IBB $XBI )

by John F. Heerdink, Jr. March 11, 2026 231Views 0Likes

The timing could hardly be better: as controversial FDA leader, Vinay Prasad, exits FDA’s CBER and sentiment tilts back toward innovation, GeoVax Labs (NASDAQ: GOVX) has launched formal outreach around future procurement of its GEO‑MVA mpox/smallpox vaccine. The company is effectively telling…

GeoVax Expands Gedeptin Strategy: Riding Merck’s Keytruda Wave in a $200 Billion IO Market -( $GOVX $MRK $IBB $XBI )

by John F. Heerdink, Jr. February 18, 2026 365Views 0Likes

GeoVax’s (NASDAQ: GOVX) latest move to lock down combination rights for its Gedeptin cancer platform reads less like a routine licensing notice and more like an oncology strategy upgrade—complete with optionality, IP leverage, and a quietly ambitious grab for front-line real estate…

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

by John F. Heerdink, Jr. January 21, 2026 214Views 0Likes

Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…

The Year of the Bispecific: Biotech’s Double-Edged Breakout -( $ARKG $IBB $XBI $RHBBY $AMGN $JNJ )

by Vista Partners LLC December 10, 2025 195Views 0Likes

If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…

Reinventing Diabetes Care: Modular Medical’s Bold Bet on Simpler, Smarter Insulin Delivery – ( $MODD )

by John F. Heerdink, Jr. August 7, 2025 272Views 0Likes

Modular Medical (NASDAQ: MODD), a potential disruptor in diabetes care technology, is rapidly moving from visionary concept to tangible innovation as it propels its FDA cleared MODD1 insulin patch pump toward commercial launch. The company has recently validated its MODD1 cartridge manufacturing…

Soleno Therapeutics Secures FDA Approval for VYKAT XR: A Groundbreaking Moment for Prader-Willi Syndrome Treatment – $SLNO $IBB $XBI

by John F. Heerdink, Jr. March 27, 2025 256Views 0Likes

In a move that has sent shockwaves of excitement through the biotech community, Soleno Therapeutics (NASDAQ: SLNO, Up approx. +40% on Thursday) has successfully secured FDA approval for VYKAT XR, the first-ever treatment for hyperphagia in Prader-Willi syndrome (PWS). This rare genetic…

Amgen

Your Guide To Staying Informed In The Markets